Frankfurt
31.07.26 | 08:20
4,660 Euro
+4,02 % +0,180
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Singtel explores dual-listing for data centre arm Nxera - report | 4 | The Edge Markets | ||
| 30.06. | Nxera Receives $10 Mln Milestone Payment From AbbVie | 448 | AFX News | TOKYO (dpa-AFX) - Nxera Pharma Co., Ltd. (SOLTF) on Tuesday said it received a $10 million milestone payment from AbbVie (ABBV) after achieving a fourth R&D milestone under their multi-target... ► Artikel lesen | |
| 30.06. | Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases | 190 | GlobeNewswire (Europe) | This marks the fourth R&D milestone achieved under the collaboration, and the second in 2026, reflecting the steady progress of development under the collaborationUnder the terms of the agreement... ► Artikel lesen | |
| 10.06. | Nxera Pharma: Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery | 1 | GlobeNewswire (USA) | ||
| 02.06. | Nxera Pharma: Nxera's Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea | 129 | GlobeNewswire (Europe) | Orphan Drug Designation (ODD) recognizes Duchenne muscular dystrophy as a rare disease with significant unmet medical need without an established treatment in South Korea.Global Innovative Products... ► Artikel lesen | |
| NXERA PHARMA Aktie jetzt für 0€ handeln | |||||
| 11.05. | Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing | 317 | GlobeNewswire (Europe) | New company ("NewCo") co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.In return for granting an exclusive worldwide license to the program, Nxera... ► Artikel lesen | |
| 08.05. | Nxera Pharma verklagt OMass Therapeutics wegen Patentverletzung | 4 | Investing.com Deutsch | ||
| 08.05. | Nxera Pharma sues OMass Therapeutics over patent infringement | 2 | Investing.com | ||
| 08.05. | Nxera Pharma: Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology | 790 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge and London, UK, 8 May 2026 - Nxera Pharma Co., Ltd. ("Nxera Pharma" or "the Company"; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited ("Nxera")... ► Artikel lesen | |
| 01.05. | Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026 | 407 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 1 May 2026 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter... ► Artikel lesen | |
| 20.04. | Nxera Pharma To Receive $10 Mln Milestone Payment From AbbVie Under Neurology Collaboration | 418 | AFX News | TOKYO (dpa-AFX) - Nxera Pharma Co., Ltd. (4565.T, SOLTF), a research-based biopharmaceutical company, on Monday announced that it will receive a $10 million milestone payment from AbbVie Inc.... ► Artikel lesen | |
| 20.04. | Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases | 219 | GlobeNewswire (Europe) | This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipelineUnder the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion... ► Artikel lesen | |
| 16.04. | TM Nxera Tops Out AI-Ready Johor Data Centre, Moves Towards 2H2026 Ops | 1 | BusinessToday | ||
| 15.04. | Nxera Pharma: Notice of Issuance of New Shares in Connection with the Introduction of the Employee Stock Ownership Plan, Matters Relating to Stock Units and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Prior ... | 3 | GlobeNewswire (USA) | ||
| 14.04. | Nxera Pharma's QUVIVIQ (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia | 603 | GlobeNewswire (Europe) | Nxera's partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with approximately 4-5 million patients, with launch planned during 2026QUVIVIQ® is approved through Taiwan's... ► Artikel lesen | |
| 14.04. | TM Nxera tops out its first AI data centre in Johor | - | Developing Telecoms | ||
| 13.04. | Singtel's Nxera and Telekom Malaysia top out data center in Johor | 2 | DatacenterDynamics | ||
| 13.04. | Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia | 339 | GlobeNewswire (Europe) | NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with NeurocrineNxera... ► Artikel lesen | |
| 09.04. | Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases | 628 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 09 April 2026 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that it has achieved a second development milestone under its multi-target... ► Artikel lesen | |
| 01.04. | Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly | 312 | GlobeNewswire (Europe) | Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disordersCentessa's OX2R agonist pipeline was jointly discovered by Nxera and Centessa, and... ► Artikel lesen |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,770 | +0,30 % | Keine Ende der Rallye in Sicht: Diese Biotechnologie-Aktie bietet für ihr Geld so viel wie kaum eine zweite! | © Foto: ZUMAPRESS.com | La Nacion - picture allianceTrotz eines enorm starken Wachstums und einer günstigen Unternehmensbewertung ist Halozyme noch immer ein Nischenwert. Das dürfte nicht mehr lange... ► Artikel lesen | |
| NOVARTIS | 135,74 | +0,28 % | BERENBERG stuft NOVARTIS AG auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Novartis von 110 auf 120 Franken angehoben und die Einstufung auf "Hold" belassen. Mit der Anpassung trage sie den soliden... ► Artikel lesen | |
| GILEAD SCIENCES | 113,32 | +0,35 % | Cantor Fitzgerald reiterates Gilead Sciences stock rating at Overweight | ||
| SANOFI | 75,00 | -0,32 % | BERNSTEIN RESEARCH stuft SANOFI auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Sanofi auf "Outperform" mit einem Kursziel von 107 Euro belassen. Die neue Konzernchefi unternehme weitere... ► Artikel lesen | |
| ABBVIE | 218,30 | +0,28 % | Regulatory tracker: Ahead of FDA verdicts, EU clears AbbVie's Rinvoq in alopecia, vitiligo | ||
| ROCHE | 377,90 | +0,19 % | ANALYSE-FLASH: Bernstein hebt Ziel für Roche auf 434,50 Franken - 'Outperform' | NEW YORK (dpa-AFX Broker) - Das US-Analysehaus Bernstein Research hat das Kursziel für Roche von 395,00 auf 434,50 Franken angehoben und die Einstufung auf "Outperform" belassen. Da sich die Forschungs-... ► Artikel lesen | |
| ABBOTT LABORATORIES | 91,92 | +0,24 % | ABBOTT LABORATORIES - 10-Q, Quarterly Report | ||
| HAEMATO | 13,300 | +0,76 % | Dividendenbekanntmachungen (08.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A2 MILK COMPANY LIMITED NZATME0002S8 0,4135 NZD 0,2059 EUR AGRANA BETEILIGUNGS-AG AT000AGRANA3 - 0,35 EUR BANK OF CHONGQING CO LTD CNE100001QN2 0... ► Artikel lesen | |
| INCYTE | 103,70 | +0,05 % | Incyte: Opzelura (Ruxolitinib)-Creme ist der erste steroidfreie topische JAK-Hemmer, der in der Europäischen Union für Erwachsene mit mittelschwerer atopischer Dermatitis zugelassen wurde | Die Zulassung durch die Europäische Kommission stützt sich auf Daten der Phase-3b-Studie TRuE AD4, die zeigten, dass die Opzelura (Ruxolitinib)-Creme in Woche 8 beide primären Endpunkte erreichte... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 74,46 | -0,21 % | Is the Options Market Predicting a Spike in Edwards Lifesciences Stock? | ||
| HALEON | 4,283 | -1,31 % | Haleon plc - 6-K, Report of foreign issuer | ||
| BIONANO GENOMICS | 1,065 | 0,00 % | Bionano Genomics: Bionano Announces Hiring of Chief Scientific Officer | SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 61,02 | -1,52 % | Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect? | ||
| GRIFOLS | 10,105 | -0,35 % | Grifols H1 Profit Rises 29%; Backs FY26 Outlook | MADRID (dpa-AFX) - Grifols S.A. (GRFS) on Tuesday reported higher profit for the first half of 2026, supported by growth in its Biopharma business. The company also reaffirmed its full-year... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 177,30 | -0,53 % | Alnylam Falls 29% After Reporting Q2 Results | WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) plunged after lowering its full-year TTR revenue guidance, overshadowing strong second-quarter revenue growth and a return to profitability.... ► Artikel lesen |
NXERA PHARMA CO LTD gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,180 (+4,02 %) liegt der Kurs bei 4,660 Euro. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NXERA PHARMA CO LTD finden Sie auf Wallstreet Online.